Idecabtagene Vicleucel Infusion Suppliers & Bulk Manufacturers
Available Forms: IV Infusion
Available Strengths: Approved for relapsed/refractory multiple myeloma, with dosing based on patient weight, delivering a personalized, targeted therapy to eliminate cancer cells
Reference Brands: Abecma(US & EU)
Category:
Cell & Gene Therapies
Idecabtagene vicleucel (Abecma) is a CAR T-cell therapy that reprograms a patient’s T cells to target BCMA, a protein on myeloma cells. It provides targeted, rapid cancer cell eradication, leading to durable responses, improved survival, and enhanced quality of life for relapsed/refractory multiple myeloma patients when administered in specialized centers.
Idecabtagene Vicleucel Infusion is available in IV Infusion
and strengths such as Approved for relapsed/refractory multiple myeloma, with dosing based on patient weight, delivering a personalized, targeted therapy to eliminate cancer cells.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Idecabtagene Vicleucel Infusion is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Idecabtagene Vicleucel Infusion can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Idecabtagene vicleucel (Abecma) is regulated in the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in line with GMP and MDR standards. FDA approval involved extensive clinical validation, safety assessment, and comparability data. In the EU, CE marking certifies conformity with MDR regulations. The product undergoes validation, stability testing, and audits, with comprehensive documentation including clinical trial results, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to innovative, life-saving CAR T-cell therapies for multiple myeloma and other hematologic malignancies globally, supporting improved patient outcomes and advanced cancer care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing